|
Market Closed –
|
5-day change | 1st Jan Change | ||
|
19.11 USD |
-1.49% | +3.07% | -35.87% | |
Published on 05/31/2025 at 23:20
Presenter Speech
William Doyle (Executives)
Hello. Good evening, everyone. Welcome to Chicago, welcome to ASCO, and welcome to Novocure’s post-PANOVA-3 investor event. It’s my great pleasure to host
M
|
NovoCure Limited – Special Call |
11:20pm |
|
|
Zai Lab and Novocure Announce Results from the Phase 3 Panova-3 Trial of Tumor Treating Fields Therapy for Pancreatic Cancer to Be Presented At 2025 Asco Annual Meeting |
May. 31 |
CI |
|
Novocure Says Ttfields Therapy Shows Significant Improvement In Overall Survival For Pancreatic Cancer |
May. 31 |
RE |
|
Novocure Announces Results from the Phase 3 Panova-3 Trial of Novocure’s Tumor Treating Fields Therapy for Pancreatic Cancer to Be Presented At 2025 ASCO Annual Meeting |
May. 31 |
CI |
|
Novocure Announces Upcoming Investor Events |
May. 27 |
RE |
|
NovoCure’s Q1 Loss Narrows, Revenue Rises |
Apr. 24 |
MT |
|
NovoCure Limited, Q1 2025 Earnings Call, Apr 24, 2025 |
Apr. 24 |
|
|
Earnings Flash (NVCR) NOVOCURE Posts Q1 Revenue $155M, vs. FactSet Est of $146.9M |
Apr. 24 |
MT |
|
Earnings Flash (NVCR) NOVOCURE Posts Q1 Loss $-0.31 Per Share, vs. FactSet Est of $-0.46 |
Apr. 24 |
MT |
|
NovoCure Limited Reports Earnings Results for the First Quarter Ended March 31, 2025 |
Apr. 24 |
CI |
|
Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of Its Tumor Treating Fields Therapy for Pancreatic Cancer as A Late-Breaking Oral Presentation At the 2025 ASCO Annual Meeting |
Apr. 23 |
CI |
|
Sector Update: Health Care Stocks Rise Late Afternoon |
Apr. 22 |
MT |
|
NovoCure Says Optune Lua Device Gets CE Mark to Treat Lung Cancer |
Apr. 22 |
MT |
|
Novocure’S Optune Lua® Receives CE Mark Approval |
Apr. 22 |
RE |
|
Novocure Insider Sold Shares Worth $266,126, According to a Recent SEC Filing |
Mar. 03 |
MT |
|
Novocure Insider Sold Shares Worth $296,257, According to a Recent SEC Filing |
Mar. 03 |
MT |
|
NovoCure’s Q4 Loss Widens, Revenue Rises |
Feb. 27 |
MT |
|
NovoCure Limited, Q4 2024 Earnings Call, Feb 27, 2025 |
Feb. 27 |
|
|
Earnings Flash (NVCR) NOVOCURE Reports Q4 Revenue $161.3M, vs. FactSet Est of $161.3M |
Feb. 27 |
MT |
|
NovoCure Limited Reports Earnings Results for the Fourth Quarter Ended December 31, 2024 |
Feb. 27 |
CI |
|
NovoCure Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 |
Feb. 27 |
CI |
|
C Worldwide Healthcare Select up 5.8% in January – divests Illumina |
Feb. 12 |
FW |
|
NovoCure Opens New Global Headquarters in Switzerland |
Jan. 22 |
MT |
|
Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland |
Jan. 22 |
CI |
|
NovoCure Limited Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-15-2025 09:00 AM |
Jan. 15 |
NVCR: Dynamic Chart
Quarterly revenue – Rate of surprise
Select your edition
All financial news and data tailored to specific country editions
